Lu-PSMA prostate cancer data study
Part of Cancer, Kidney & urinary clinical trials.
This study collects information (like scans and blood tests) from men with prostate cancer who are about to start Lu-PSMA therapy. The goal is to track how the cancer responds and learn more about its features during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You understand the study information and can give your permission to participate.
- You are scheduled to start Lu-PSMA treatment for your prostate cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses two types of PET scans (PSMA and FDG) to see how well a radioactive therapy called 177Lu-PSMA might work for men with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy.
This study is testing whether a special scan (dosimetry) can help predict how well PSMA radioligand therapy works for men with advanced prostate cancer that has spread. The therapy uses a radioactive drug to target and kill cancer cells that have a protein called PSMA.
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
This trial studies blood tests (liquid biopsies) in men with metastatic prostate cancer that no longer responds to hormone therapy or chemotherapy and who are receiving a type of radiation therapy called PSMA RLT. The goal is to see if these blood tests can provide useful information about the cancer and treatment response.
This trial uses a blood test to measure tumor DNA and see if men with advanced prostate cancer can safely stop treatment with a drug called 177Lu-PSMA-617 earlier than usual, or switch to chemotherapy. It may help reduce side effects while still controlling the cancer.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
Hear when a new Prostate Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.